# | Aladdin ID | Assay Type | Description | Organism | Compounds | Reference | BAO Format | Source | |
---|---|---|---|---|---|---|---|---|---|
1. | ALA941657 | B | Inhibition of human IGF1R expressed in Sf21 cells by time-resolved fluorescence assay | Homo sapiens | 31 | cell-based format | Scientific Literature | ||
2. | ALA941658 | B | Inhibition IGF1R phosphorylation in human MiaPaCa2 cells | Homo sapiens | 31 | cell-based format | Scientific Literature | ||
3. | ALA3215232 | F | PubChem BioAssay. HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set12. (absACnn = the concentration at which the curve crosses threshold nn uM) (Class of assay: confirmatory) | 33 | cell-based format | PubChem BioAssays | |||
4. | ALA3215243 | F | PubChem BioAssay. Luminescence cell-based Retest at Dose assay to determine EWS/Fli1 dependent TC71 mammalian cell cytotoxity Measured in Cell-Based System Using Plate Reader - 7014-04_Inhibitor_Dose_DryPowder_Activity. (absACnn = the concentration at which the curve crosses threshold nn uM) (Class of assay: confirmatory) | 60 | cell-based format | PubChem BioAssays | |||
5. | ALA3215274 | F | PubChem BioAssay. Luminescence cell-based Retest at Dose assay to determine EWS/Fli1 dependent A673 mammalian cell cytotoxity Measured in Cell-Based System Using Plate Reader - 7014-03_Inhibitor_Dose_DryPowder_Activity. (absACnn = the concentration at which the curve crosses threshold nn uM) (Class of assay: confirmatory) | 62 | cell-based format | PubChem BioAssays | |||
6. | ALA3214834 | F | PubChem BioAssay. A549 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-06_Inhibitor_Dose_DryPowder_Activity_Set12. (absACnn = the concentration at which the curve crosses threshold nn uM) (Class of assay: confirmatory) | 50 | cell-based format | PubChem BioAssays | |||
7. | ALA3214885 | F | PubChem BioAssay. Luminescence Cell-Based Primary HTS to identify inhibitors of the oncoprotein EWS/Fli transcriptional activity Measured in Cell-Based System Using Plate Reader - 7014-01_Inhibitor_Dose_DryPowder_Activity. (absACnn = the concentration at which the curve crosses threshold nn uM) (Class of assay: confirmatory) | 67 | cell-based format | PubChem BioAssays | |||
8. | ALA3214961 | F | PubChem BioAssay. HEK293 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader_7071-01_Inhibitor_Dose_DryPowder_Activity_Set15. (absACnn = the concentration at which the curve crosses threshold nn uM) (Class of assay: confirmatory) | 23 | cell-based format | PubChem BioAssays | |||
9. | ALA3882755 | B | Inhibition of human IGF1R kinase domain (M954 to C1367 residues) un-phosphorylated apo-enzyme form expressed in baculovirus based expression system using poly-EY peptide incubated for 2 hrs by luciferase-luciferin coupled chemiluminescent assay | Homo sapiens | 526 | assay format | Patent Bioactivity Data | ||
10. | ALA3882756 | B | Inhibition of human IGF1R kinase domain (M954 to C1367 residues) tri-phosphorylated enzyme form expressed in baculovirus based expression system using poly-EY peptide incubated for 2 hrs by luciferase-luciferin coupled chemiluminescent assay | Homo sapiens | 526 | assay format | Patent Bioactivity Data | ||
11. | ALA3885749 | B | IGF1R diphosphorilated was immobilized on a Biacore CM5 chip at 25 degrees C with 2uM K04355 and a flow rate of 30 uL/min using amine coupling at pH 4.50 according to Biacore standard protocol. Data sets were processed and analyzed using the software Biacore 4000 Evaluation. Solvent corrected and double-referenced association and dissociation phase data were fitted to a simple 1:1 interaction model with mass transport limitations | Homo sapiens | 27 | single protein format | K4DD Project | ||
12. | ALA4049313 | B | Inhibition of Ebolavirus glycoprotein/matrix protein VP40 entry in human HeLa cells after 4.5 hrs beta-lactamase reporter assay | Ebolavirus | 28 | cell-based format | Scientific Literature | ||
13. | ALA4049314 | T | Selectivity index, ratio of cytotoxic activity for HEK293 cells to IC50 for Ebolavirus glycoprotein/matrix protein VP40 entry in human HeLa cells | 14 | cell-based format | Scientific Literature | |||
14. | ALA4049315 | T | Selectivity index, ratio of cytotoxic activity for human HeLa cells to IC50 for Ebolavirus glycoprotein/matrix protein VP40 entry in human HeLa cells | 14 | cell-based format | Scientific Literature | |||
15. | ALA4049316 | F | Antiviral activity against Ebolavirus Mayinga infected in African green monkey Vero E6 cells after 72 hrs by eGFP assay | Ebolavirus | 4 | assay format | Scientific Literature | ||
16. | ALA4049317 | B | Binding affinity to Ebolavirus glycoprotein/matrix protein VP40 at 50 uM incubated for 10 mins by thermal shift assay | Ebolavirus | 12 | assay format | Scientific Literature | ||
17. | ALA4303805 | F | Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of Caco-2 cells at 10 uM after 48 hours by high content imaging | Homo sapiens | 5,612 | organism-based format | SARS-CoV-2 Screening Data 2020-21 | ||
18. | ALA4495582 | F | SARS-CoV-2 3CL-Pro protease inhibition percentage at 20µM by FRET kind of response from peptide substrate | Severe acute respiratory syndrome coronavirus 2 | 7,212 | assay format | SARS-CoV-2 Screening Data 2020-21 | ||
19. | ALA4513082 | F | Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of VERO-6 cells at 10 uM after 48 hours exposure to 0.01 MOI SARS CoV-2 virus by high content imaging | Chlorocebus sabaeus | 7,212 | organism-based format | SARS-CoV-2 Screening Data 2020-21 | ||
20. | ALA4808149 | B | Enzymatic assay of human HDAC6 with commercial peptide substrate | Homo sapiens | 5,603 | single protein format | Fraunhofer HDAC6 |